#meningococcus

Meningococcal Vaccines Industry Research Report Analysis by MRFR. The global market supply is expected to reach USD 203 Million by 2025. The Market segmentation is on the basis of treatment, end user, and region - forecast till 2025

Meningococcal Vaccines Market overview 

The global Meningococcal vaccines market showcases the rising cases of this disease with the increasing demand for vaccines. According to the report, almost 10 to 15 in 100 people get affected with meningococcal disease. The escalation in positive result cases and the need for vaccines is boosting its demand in the global market. The Meningococcal vaccines market has risen upto USD 172 million in the year 2019 and the global supply is estimated to be 203 million doses for the forecast period till 2025.  

Despite broad and effective commitment from the global health community in meningitis A (MENA) vaccination in the meningitis belt, low manufacturing capacity and high prices across other meningococcal vaccine types have hindered access to these vaccines over the past several years. A more in-depth knowledge will benefit addressing these long-standing access issues and the development of the WHO global roadmap for overcoming meningitis by 2030. This is expected to set goals for disease control and vaccination for meningococcal meningitis on a global level.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/8622

Meningococcal Vaccines Market Key Players

Some of the key players in the Global Meningococcal Vaccines Market are Baxter International, Pfizer Inc., Novartis Pharmaceuticals Canada Inc, Sanofi S.A., JN-International Medical Corporation, Biomed Pvt. Ltd., Serum Institute of India Ltd., and GlaxoSmithKline among others.

Meningococcal Vaccines Market segmentation 

The global Meningococcal vaccines market is a booming market with a lot of investment and developments. The Global Meningococcal Vaccines Market has been segmented based on treatment and end-user.

Based on the treatment, the global product market can be divided into polysaccharide, meningococcal A conjugate vaccine, and subcapsular vaccine. The meningococcal conjugate vaccine is mostly used in mass campaigns in affected regions of Africa. Since 2010, the demand for such vaccines has been uncertain, based on the national immunization programs that are being adopted based on the country’s effectiveness and readiness to tackle the disease. Moreover, the demand and supply for Subcap MenB vaccines is a desirable combination that will moderate the global product scenario. 

By the end-user, the global vaccine market can be split into research laboratories, hospital and clinical, and academic institutes. The hospitals and clinics segment holds major share in the global market for meningococcal vaccines.

Meningococcal Vaccines Market Regional analysis 

In the global market, China is expected to have the largest market share, which accounts for approximately 35% of the global demand. This is primarily due to polysaccharide products, which currently comprise 84% of China’s demand.

During 2016-2018, UNICEF introduced the meningococcal conjugate vaccine in 26 countries and Ghana was the first country in Africa to receive this vaccination. Currently, the meningococcal vaccine has reached across different regions, in the most remote locations, and has increased in demand and supply in the global market.  

Meningococcal Vaccines Industry news 

In 2018, Pfizer granted FDA Breakthrough Therapy designation for Trumenba (Meningococcal Group B Vaccine). This vaccine plays a major role in the prevention of invasive meningococcal B disease in children aged 1 to 9 years.

In 2018, GSK’s (GlaxoSmithKline) meningitis B vaccine Bexsero received breakthrough therapy designation from the US FDA for prevention of Invasive Meningococcal Disease for children 2-10 years of age.

Browse Complete Report with TOC with COVID-19 Impact Analysis @ https://www.marketresearchfuture.com/reports/meningococcal-vaccines-market-8622

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

+1 646 845 9312

Email: [email protected]

The Spanish Flu pandemic of 1918 was caused by an experimental vaccine? A conspiracy theory I hadn’t heard of before…

It’s been a hundred years since the beginning of the great influenza pandemic of 1918. It was truly a monumental and horrific pandemic, lasting two years, infecting a half a billion people, and killing at least 50 million people worldwide, roughly 700,000 in the US, making it one of the deadliest pandemics in human history. Known colloquially as the “Spanish flu,” the strain of influenza…

Meningitis By Dr Patricia Thompson

A new vaccine, for Meningococcus B, will soon be available for babies. What, another vaccine? Do we really need it? I would say – absolutely yes. Meningococcus causes meningitis, and blood infection (septicaemia) – sometimes leading to limb amputation or brain damage. Approximately 1:10 people affected die. As a paediatrician, I’ve seen healthy children become seriously ill within hours. Most…

Neisseria meningitidis.

Also known as: Meningococcus

Industry of interest: Healthcare

Classification: Bacteria